Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
MMF in IgA: Inching into the MAINstream?
Mycophenolate in IgAN - The Visual Abstract
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan
This week, we will discuss the use of LLMs for the diagnosis of complex nephrology cases. Can AI help nephrologists nail the correct diagnosis?
MERCURI-2 reports that dapagliflozin cuts postoperative AKI after cardiac surgery, but the headline result is mostly a urine-output story, not a creatinine one. That matters: urine output after surgery is easily swayed by anesthesia, fluid shifts, vasopressors, and a diuretic drug in the mix. Until dapagliflozin shows it protects kidney function, not just urine output.
This week, we will discuss SODaBIC trial: with ICU acidosis driven by multiple overlapping mechanisms, is bicarbonate infusion supported by robust evidence, or does it persist mainly out of habit rather than physiology?
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
Welcome to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) April 28, 2023
✳️10 tweets #NephJC catch-up ✳️
On 3/28-29, #NephJC reviewed the MAIN trial (Mycophenolate monotherapy in IgA Nephropathy). Here are some pearls from the chat ⬇️ pic.twitter.com/RUepFSEwXx
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan